Activity Dates: 04/20/2009 - 04/20/2012
This course is closed. Please look for other available products in CPNP University.
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.
While there is no doubt that medication treatments have demonstrated efficacy for improving clinical symptoms and decreasing rates of relapse for individuals with schizophrenia, many aspects of the illness have not responded or have only partially responded to pharmacotherapy. Multiple psychosocial treatments have been pursued to address these needs. This presentation will focus on two primary types of treatment: Cognitive Behavior Therapy (CBT) and Cognitive Rehabilitation. CBT is designed to decrease the frequency, severity, and the impact on functional outcome of positive symptoms that persist despite adequate medication treatment.
CBT is based partly on the evidence that emotional processes, information-processing deficits and reasoning and appraisal biases contribute to the formation and maintenance of delusions and hallucinations and that these processes can be changed through cognitive intervention. The therapist in CBT works to understand the client’s perspective regarding specific symptoms and over time to develop ways to test and evaluate these beliefs. Research has demonstrated that individuals participating in CBT have better insight into their illness, and fewer positive symptoms than those in control treatments. Cognitive rehabilitation strategies target deficits in memory, attention and planning that underlie problems in independent living, work, and social role functioning. Cognitive remediation (CR) is an approach using practice with pen and paper or computerized tests of these cognitive skills to improve deficits. Research has shown the participants in CR improve in specific cognitive skills and have better work outcomes than those in control treatments.
Cognitive Adaptation Training (CAT) uses environmental supports such as signs, checklists, alarms, pill containers, and the organization of belongings to bypass cognitive deficits and to cue and sequence adaptive behavior in the home or work environment. CAT has been found to improve specific target behaviors such as hygiene and medication adherence, global functional outcome, and amotivation, and to reduce rates of relapse in comparison to control treatments. While medication treatments are an important foundation, the use of psychosocial approaches is necessary to produce the best outcomes for individuals with schizophrenia.
You will proceed through the following steps to satisfactorily complete this course:
This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.
Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows Vista and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Dawn Velligan, PhDView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.1 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-09-008-H01-P (1.0 contact hours).
ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This programming was supported in part by grants from Bristol-Myers Squibb, Forest Laboratories, Inc., Lilly, Schering-Plough, Cyberonics, Shire, and Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.